hiv-1

Documents about hiv-1

• An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)#904840ClinicalTrials.gov
• HIV‐1 Non Group‐M Phenotypic Susceptibility to Ibalizumab#7827HAL (France)
• Phase I/IIa Dose-escalation Clinical Study of VAC-3S#432915ClinicalTrials.gov
• ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study#854481ClinicalTrials.gov
• A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)#307307ClinicalTrials.gov
• Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community Practice in Sydney, Australia#813287ClinicalTrials.gov
• Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection#840302ClinicalTrials.gov
• The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine#884739ClinicalTrials.gov
• BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes#893663ClinicalTrials.gov
• Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study#914903ClinicalTrials.gov
• Genotyping FcɣRs Genes of HIV-1 Patients "Progressor": Correlation With the Changing Profile of the Infection#966519ClinicalTrials.gov
• Molecular Dynamics Simulations of 2‐Amino‐6‐arylsulphonylbenzonitriles Analogues as HIV Inhibitors: Interaction Modes and Binding Free Energies#471816HAL (France)
• Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults#414339ClinicalTrials.gov
• Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children#873408ClinicalTrials.gov
• The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients#966352ClinicalTrials.gov
• IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients#915757ClinicalTrials.gov
• Unveiling the Impact of Drug-Sensitive Mutations on HIV-1 Protease Dynamics: A Molecular Dynamics Simulation Study of the T12A, L63Q, and H69N Variants#213218HAL (France)
• A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study#810555ClinicalTrials.gov
• Dibenzoacridinium derivatives: a new class of G-quadruplex ligands with anti-HIV-1 properties#378078HAL (France)
• An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen#843766ClinicalTrials.gov
• Could AAV-vectored delivery of broadly neutralizing antibodies (bNAbs) reduce virologic failure in children diagnosed with perinatal HIV?#311608Europe PMC
• Retrovirus Epidemiology Donor Study-II (REDS-II)#851841ClinicalTrials.gov
• MicroRNAs Regulated by Pregnancy Target Antiviral and Cancer Immunity Overlapping with the HIV Interactome#1001606ODU Digital Commons
• Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses#274245HAL (France)
• A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients#804121ClinicalTrials.gov
• Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV#283106ClinicalTrials.gov
• A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers#349998ClinicalTrials.gov
• Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy#836882ClinicalTrials.gov
• Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers#217088ClinicalTrials.gov
• A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)#303567ClinicalTrials.gov
• A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160#407779ClinicalTrials.gov
• PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial#826978ClinicalTrials.gov
• VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1#828958ClinicalTrials.gov
• An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients#841878ClinicalTrials.gov
• Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection#859724ClinicalTrials.gov
• A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients#890696ClinicalTrials.gov
• Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy#909268ClinicalTrials.gov
• Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment#876734ClinicalTrials.gov
• Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)#803109ClinicalTrials.gov
• Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years#904028ClinicalTrials.gov
• A novel small-molecule inhibitor of HIV-1 entry#7885HAL (France)
• MARCH Central Nervous System Substudy#867278ClinicalTrials.gov
• Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)#827225ClinicalTrials.gov
• Presentation 2_HIV-1 molecular transmission networks among MSM in Ningxia, China (2018–2024): insights into local transmission dynamics and drug resistance.pptx#266439Figshare
• Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.#879532ClinicalTrials.gov
• A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)#900726ClinicalTrials.gov
• Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals#910581ClinicalTrials.gov
• Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns#863517ClinicalTrials.gov
• Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria#123490ClinicalTrials.gov
• "Metal-based compounds in antiviral and Antiparasitic research: Mechanistic insights from HIV NCp7 and leishmaniasis case studies".#190383PubMed